[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].. Expérience de l’institut Paoli-Calmettes concernant la chimiothérapie à haute dose et autogreffe de cellules souches hématopoïétiques pour la prise en charge des cancers mammaires : impact du statut Her2 et BRCA1/2

Archive ouverte

Boudin, Laurys | Chabannon, Christian | Sfumato, Patrick | Sabatier, Renaud | Bertucci, François | Tarpin, Carole | Provansal, Magali | Houvenaeghel, Gilles | Lambaudie, Eric | Tallet, Agnès | Resbeut, Michel | Charafe-Jauffret, Emmanuelle | Calmels, Boris | Lemarié, Claude | Boher, Jean-Marie | Extra, Jean-Marc | Viens, Patrice | Gonçalves, Anthony

Edité par CCSD ; Elsevier -

International audience. Studies evaluating chemotherapy high dose chemotherapy with autologous haematopoietic stem cell transplantation (HDC-ACSH) in the treatment of metastatic (MBC), locally advanced (LABC) and inflammatory (IBC) breast cancer have in common lack of biomarker information, in particular the HER2 status.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion